ArticleFrontiers in medicine2025
Development and validation of a postoperative risk model for esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) remains a highly aggressive malignancy with a significant risk of recurrence, even after curative treatment. While neoadjuvant immunochemotherapy (nICT) combined with minimally invasive esophagectomy (MIE) has shown promise in improving outcomes for patients with locally advanced, resectable ESCC, the factors contributing to early postoperative recurrence remain unclear. This study aims to identify high-risk factors for short-term recurrence and develop a predictive model for recurrence in patients with locally advanced, resectable ESCC treated with nICT followed by MIE (McKeown approach). Methods: Patients with locally advanced, resectable ESCC who underwent nICT followed by MIE at Gaozhou People's Hospital between 1 January 2019, and 1 January 2022, were consecutively included in the training set. Patients who received the same treatment at Union Hospital of Fujian Medical University during the same period were included as the validation set. A recurrence prediction model was developed based on these cohorts. Results: A total of 362 patients treated with nICT were included, including 218 in the training set and 144 in the validation set. Least absolute shrinkage and selection operator regression identified the 10 most significant variables associated with recurrence: smoking history, drinking history, diarrhea, number of lymph nodes dissected, number of lymph node dissection stations, pathological N (pN) stage, pathological TNM stage, tumor regression grade, nerve invasion, and postoperative arrhythmia. Multivariate regression analysis further identified pN+ and nerve invasion as independent high-risk factors for recurrence. The recurrence prediction model demonstrated strong discriminatory ability, with an area under the curve of 0.92 in the training set and 0.91 in the validation set at 3 years postoperatively. Survival analysis showed a statistically significant difference ( Conclusion: Patients with locally advanced ESCC treated with nICT followed by MIE who have a high pN stage and pathological evidence of nerve invasion may benefit from intensified adjuvant therapy to improve long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.